Curis (CRIS) Stock Price, News & Analysis

Company Overview

Curis, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development programs target molecular pathways involved in tumor growth, survival and immune regulation, with the goal of addressing cancers that have limited treatment options.

Curis’ lead investigational product is emavusertib, an orally administered inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies involving patients with hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain lymphomas. As an investigational medicine, emavusertib has not been established as safe or effective for any use unless approved by the applicable regulatory authorities.

Founded in 1997 and headquartered in Lexington, Massachusetts, Curis has historically advanced cancer therapies through internal research and strategic collaborations. Its earlier programs included hedgehog-pathway inhibitor vismodegib, which was developed with Genentech and later approved in the United States as Erivedge for certain advanced basal cell carcinomas. Curis also has a collaboration with Aurigene Discovery Technologies for the discovery and development of small-molecule oncology therapies. The company is led by President and Chief Executive Officer James E. Dentzer.

Key Stats

• Today's Range: $0.81 to $0.96
• 50-Day Range: $0.83 to $5.15
• 52-Week Range: $0.81 to $34.80
• Volume: 285,622 shs
• Average Volume: 142,476 shs
• Market Capitalization: $1.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.00
• Consensus Rating: Hold

Curis Stock Analysis - MarketRank™

Curis scored higher than 71% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Curis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Curis has a consensus price target of $43.00, representing about 5,081.3% upside from its current price of $0.83.

Amount of Analyst Coverage

Curis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Curis are expected to decrease in the coming year, from ($15.65) to ($57.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Curis is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Curis is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Curis has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.51% of the float of Curis has been sold short.

Short Interest Ratio / Days to Cover

Curis has a short interest ratio ("days to cover") of 0.54, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Curis has recently decreased by 58.97%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Curis does not currently pay a dividend.

Dividend Growth

Curis does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Curis has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Curis this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for CRIS on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Curis insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.78% of the stock of Curis is held by insiders.

Percentage Held by Institutions

29.97% of the stock of Curis is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CRIS
• CIK: 1108205
• Web: www.curis.com
• Phone: (617) 503-6500
• Fax: 617-503-6501
• Employees: 24
• Year Founded: 2000

Price Target and Rating

• Average Price Target for Curis: $43.00
• High Price Target: $43.00
• Low Price Target: $43.00
• Potential Upside/Downside: +5,081.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.58 million
• Net Margins: -80.29%
• Pretax Margin: -490.33%
• Return on Equity: -2,365.94%
• Return on Assets: -200.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.49
• Quick Ratio: 0.49

Sales & Book Value

• Annual Sales: $9.44 million
• Price / Sales: 0.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.45 per share
• Price / Book: 0.10

Miscellaneous

• Outstanding Shares: 2,090,000
• Free Float: 1,969,000
• Market Cap: $1.73 million
• Optionable: No Data
• Beta: 3.01